BACKGROUND: Oral anticoagulants have been associated with greater hematoma expansion in patients with intracerebral hemorrhage (ICH). The purpose of this study was to determine whether the reported use of antiplatelet agents also results in greater hematoma expansion. METHODS: Retrospective review of patients with spontaneous supratentorial ICH diagnosed within 6 h of onset, who underwent follow-up head CT approximately 48 h later. Digital imaging analysis of initial and second CT scans was performed for comparison of hematoma volume changes between patients reporting and those not reporting antecedent antiplatelet use. Statistical analyses to determine predictors of ICH volume change and in-hospital mortality were also performed via multivariate regression models. RESULTS: Of the 70 patients included, 17 were documented as taking antiplatelet agents. Groups were comparable regarding baseline demographic, clinical and laboratory characteristics, and the timing of CT scans was similar. Patients reporting antiplatelet use experienced greater absolute increase (7.7 ml vs. 5.5 ml) and proportional increase (110% vs. 21%) in ICH volume than those not reporting antiplatelet use, but these differences were not statistically significant (P = 0.94 and 0.61 respectively; Wilcoxon test). Baseline hematoma volume tended to correlate with percentage volume increase (P < 0.1), whereas IVH was inversely associated with percent volume increase (P < 0.05). Age (P < 0.05), absolute volume increase (P < 0.005), and final volume (P < 0.001) were associated with in-hospital mortality, the rates of which were similar between the two study groups (18% vs. 17%). CONCLUSIONS: Patients reporting antiplatelet use experienced similar degrees of hematoma expansion compared to patients not reporting antiplatelet use.
BACKGROUND: Oral anticoagulants have been associated with greater hematoma expansion in patients with intracerebral hemorrhage (ICH). The purpose of this study was to determine whether the reported use of antiplatelet agents also results in greater hematoma expansion. METHODS: Retrospective review of patients with spontaneous supratentorial ICH diagnosed within 6 h of onset, who underwent follow-up head CT approximately 48 h later. Digital imaging analysis of initial and second CT scans was performed for comparison of hematoma volume changes between patients reporting and those not reporting antecedent antiplatelet use. Statistical analyses to determine predictors of ICH volume change and in-hospital mortality were also performed via multivariate regression models. RESULTS: Of the 70 patients included, 17 were documented as taking antiplatelet agents. Groups were comparable regarding baseline demographic, clinical and laboratory characteristics, and the timing of CT scans was similar. Patients reporting antiplatelet use experienced greater absolute increase (7.7 ml vs. 5.5 ml) and proportional increase (110% vs. 21%) in ICH volume than those not reporting antiplatelet use, but these differences were not statistically significant (P = 0.94 and 0.61 respectively; Wilcoxon test). Baseline hematoma volume tended to correlate with percentage volume increase (P < 0.1), whereas IVH was inversely associated with percent volume increase (P < 0.05). Age (P < 0.05), absolute volume increase (P < 0.005), and final volume (P < 0.001) were associated with in-hospital mortality, the rates of which were similar between the two study groups (18% vs. 17%). CONCLUSIONS:Patients reporting antiplatelet use experienced similar degrees of hematoma expansion compared to patients not reporting antiplatelet use.
Authors: S M Davis; J Broderick; M Hennerici; N C Brun; M N Diringer; S A Mayer; K Begtrup; T Steiner Journal: Neurology Date: 2006-04-25 Impact factor: 9.910
Authors: Pertti Saloheimo; Mikko Ahonen; Seppo Juvela; Juhani Pyhtinen; Eeva-Riitta Savolainen; Matti Hillbom Journal: Stroke Date: 2005-12-01 Impact factor: 7.914
Authors: Hagen B Huttner; Peter D Schellinger; Marius Hartmann; Martin Köhrmann; Eric Juettler; Johannes Wikner; Stephan Mueller; Uta Meyding-Lamade; Ralf Strobl; Ulrich Mansmann; Stefan Schwab; Thorsten Steiner Journal: Stroke Date: 2006-05-04 Impact factor: 7.914
Authors: Joseph P Broderick; Michael N Diringer; Michael D Hill; Nikolai C Brun; Stephan A Mayer; Thorsten Steiner; Brett E Skolnick; Stephen M Davis Journal: Stroke Date: 2007-02-08 Impact factor: 7.914
Authors: Andrew M Naidech; Sarice L Bassin; Richard A Bernstein; H Hunt Batjer; Mark J Alberts; Paul F Lindholm; Thomas P Bleck Journal: Neurocrit Care Date: 2009-12 Impact factor: 3.210
Authors: William D Freeman; Kevin M Barrett; Joseph M Bestic; James F Meschia; Daniel F Broderick; Thomas G Brott Journal: Neurocrit Care Date: 2008 Impact factor: 3.210
Authors: Craig S Anderson; Yining Huang; Ji Guang Wang; Hisatomi Arima; Bruce Neal; Bin Peng; Emma Heeley; Christian Skulina; Mark W Parsons; Jong Sung Kim; Qing Ling Tao; Yue Chun Li; Jian Dong Jiang; Li Wen Tai; Jin Li Zhang; En Xu; Yan Cheng; Stephane Heritier; Lewis B Morgenstern; John Chalmers Journal: Lancet Neurol Date: 2008-04-07 Impact factor: 44.182
Authors: Jennifer A Frontera; John J Lewin; Alejandro A Rabinstein; Imo P Aisiku; Anne W Alexandrov; Aaron M Cook; Gregory J del Zoppo; Monisha A Kumar; Ellinor I B Peerschke; Michael F Stiefel; Jeanne S Teitelbaum; Katja E Wartenberg; Cindy L Zerfoss Journal: Neurocrit Care Date: 2016-02 Impact factor: 3.210
Authors: Arne Lauer; Frieder Schlunk; Elizabeth M Van Cott; Helmuth Steinmetz; Eng H Lo; Christian Foerch Journal: J Cereb Blood Flow Metab Date: 2011-03-09 Impact factor: 6.200
Authors: Arne Lauer; Waltraud Pfeilschifter; Chris B Schaffer; Eng H Lo; Christian Foerch Journal: Lancet Neurol Date: 2013-03-18 Impact factor: 44.182